诱导结束时[18F]FDG PET对FOLL12试验中滤泡性淋巴瘤患者的无进展生存期和总生存期具有预后价值
本研究基于多中心前瞻性III期FOLL12试验,评估Deauville评分(DS)在滤泡性淋巴瘤疗效评估中的可靠性及诱导结束时(EOI)[18F]FDG PET代谢反应的预后价值。729例可分析患者中,EOI PET阳性(DS4-5)占12.1%;中位随访69个月,5年PFS在PET阴性(DS1-3)与阳性(DS4-5)患者中分别为71%与36%(HR 3.49),5年OS分别为96%与82%(HR 4.48)。结论认为DS是可靠的预后工具,且在标准臂与实验臂中均保持预后价值。
要点
- EOI PET阳性(DS4-5)占12.1%,与PET阴性(DS1-3)相比5年PFS为36% vs 71%(HR 3.49)。
- 5年PFS随DS升高而变差:DS1-2为74%,DS3为58%(HR 1.71;p=0.001),DS4-5为36%(HR 3.88;p<0.001)。
- 5年OS在EOI PET阴性(DS1-3)与阳性(DS4-5)患者中分别为96%与82%(HR 4.48;p<0.001)。
核心结论
- 本研究表明DS是评估滤泡性淋巴瘤患者EOI PET的可靠预后工具,其预后价值在标准臂和实验臂中均得以保持,使代谢影像成为评估FL疗效的稳健工具。
- 尽管为初步结果,本研究为DS3患者提供了进一步信息,这些患者被视为完全代谢缓解(CMR),但其PFS较DS1-2患者更差。
研究设计与样本
- 多中心、前瞻性、III期FOLL12试验(NCT02063685),入组未经治疗的1-3a级、II-IV期成人滤泡性淋巴瘤患者。
- 患者随机接受标准免疫化疗后利妥昔单抗维持(标准臂)对比标准免疫化疗后反应适应性诱导后管理(实验臂)。
- 基线和EOI PET为研究必需,所有PET扫描集中至WIDEN®平台,由盲法独立中心评审按DS分类。
- DS1-3判定为阴性(CMR),DS4-5判定为阳性(非CMR);主要终点为PFS,主要次要终点为OS。
- 共807例患者入组(52%女性,89%为III-IV期,40% FLIPI-2高危评分3-5),729例(90.4%)有可分析的基线和EOI PET。
主要发现
- EOI PET阳性(DS4-5)见于88/729例(12.1%)。
- 评审者间对PET阳/阴性结果的总一致率为0.92,对阳性和阴性病例的一致率分别为0.77和0.94。
- 中位随访69个月,5年随访期间登记247个事件,5年PFS为67%(95%CI:63%-70%)。
- PET阴性(DS1-3)与PET阳性(DS4-5)患者的5年PFS分别为71%(95%CI:67%-75%)和36%(95%CI:25%-46%),HR 3.49(95%CI:2.57-4.72)。
- 5年PFS随DS升高而变差:DS1-2为74%(70%-78%),DS3为58%(48%-67%;HR 1.71;p=0.001),DS4-5为36%(25%-46%;HR 3.88;p<0.001)。
关键数值与推荐
- DS1-3判定为阴性(CMR),DS4-5判定为阳性(非CMR)。
- EOI PET阳性(DS4-5)率为12.1%(88/729)。
- PET阴性(DS1-3)与阳性(DS4-5)的5年PFS分别为71%(95%CI:67%-75%)与36%(95%CI:25%-46%),HR 3.49(95%CI:2.57-4.72)。
- DS1-2、DS3与DS4-5的5年PFS分别为74%(70%-78%)、58%(48%-67%;HR 1.71;p=0.001)与36%(25%-46%;HR 3.88;p<0.001)。
- EOI PET阴性(DS1-3)与阳性(DS4-5)的5年OS分别为96%(95%CI:94-97)与82%(95%CI:72%-89%),HR 4.48;p<0.001。
临床怎么用
- 原文结论未给出具体的临床操作推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To evaluate the reliability of the Deauville score (DS) in therapy response assessment and to define the prognostic value of the metabolic response of end of induction (EOI) [18F]FDG PET (PET) in follicular lymphoma patients. METHODS: Adult patients with untreated grade 1-3a FL/ stage II-IV enrolled in the multicentre, prospective, phase III FOLL12 trial (NCT02063685) were randomized to receive standard immunochemotherapy followed by rituximab maintenance (standard arm) versus standard immunochemotherapy followed by response-adapted post-induction management (experimental arm). Baseline and EOI PET were mandatory for the study. All PET scans were centralized on the WIDEN® platform and classified according to DS in a blind independent central review. DS1-3 was considered negative (CMR), whereas DS4-5 was considered positive (not CMR). The primary endpoint was PFS. The main secondary endpoint was overall survival (OS). RESULTS: Overall, 807 follicular lymphoma patients-52% women, 89% stage III-IV disease, 40% with a high-risk FLIPI-2 score (3-5)-were enrolled in the study; 729 (90.4%) baseline and EOI PET were available for the analysis. EOI PET was positive (DS4-5) in 88/729 (12.1%) cases. Overall inter-reviewer agreement on PET pos/neg result was 0.92, while agreement on positive and negative cases was 0.77 and 0.94, respectively. The median follow-up was 69 months; 247 events were registered in the 5-yr follow-up, with a 5-yr PFS of 67% (95%CI: 63%-70%). The 5-yr PFS rate for PET neg (DS1-3) and PET pos (DS4-5) patients was 71% (95%CI: 67%-75%) and 36% (95%CI: 25%-46%), respectively, with HR 3.49 (95%CI: 2.57-4.72). Five-year PFS was worse as DS increased, with 74% (70%-78%), 58% (48%-67%; HR 1.71; p = 0.001)] and 36% (25%-46%; HR 3.88; p < 0.001) in DS1-2, DS3 and DS4-5, respectively. EOI PET maintained its prognostic value in both the standard and experimental arms. In the whole population, 5-yr OS was 94% (95%CI: 92%-96%), with 96% (95%CI: 94-97) and 82% (95%CI: 72%-89%) in EOI PET negative (DS1-3) and positive (DS4-5), respectively (HR 4.48; p < 0.001). When DS was associated with FLIPI-2, patients with DS3 or DS1-2 with high FLIPI-2 (3-5) experienced worse OS than patients with DS1-2 and low FLIPI-2 (1-2) (p = 0.003). CONCLUSION: This study shows that DS is a reliable prognostic tool to evaluate EOI PET in follicular lymphoma patients, with prognostic value maintained both in the standard and experimental arms, making metabolic imaging a robust tool to assess response in FL. Moreover, although preliminary, this study provides further information on DS3 patients, who are considered as CMR but show a less favourable PFS than DS1-2 patients.
引用
- Guerra L, Chauvie S, Fallanca F, et al. End of induction [18F]FDG PET is prognostic for progression-free survival and overall survival in follicular lymphoma patients enrolled in the FOLL12 trial. Eur J Nucl Med Mol Imaging. 2024. PMID: 38795120. doi:10.1007/s00259-024-06765-z
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。